Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.
In addition, when combined with ertapenem, used to treat infected diabetic foot ulcers, XF-73 was found to enhance ertapenem potency against methicillin-resistant staphylococcus aureus, another top priority WHO bacterial pathogen, by 8-fold.
Says the positive results open the way for further studies with multidrug resistant strains of Pseudomonas aeruginosa and MRSA to progress the combination of XF-73 with these antibacterials as potential new treatments for serious lung and DFU infections.
Current stock price: 37.88 pence
12-month change: down 73%
Copyright 2022 Alliance News Limited. All Rights Reserved.
